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ABSTRACT
Many drugs are found in the aquatic environment and are therefore a cause for 
concern. Low concentrations of active ingredients from human pharmaceuticals 
reach the environment via sewage treatment plants, mainly as a result of excretion. 
However, other routes, such as incorrect disposal and direct releases from 
manufacture, could also be of importance.  
The effects of residual drugs in the environment are not well understood. This 
thesis addresses the issue by using different genomic techniques. The evolutionary 
conservation of 1,318 human drug targets were predicted in 16 species from 
different taxonomic groups. We show that the majority of the drug targets are 
conserved in aquatic vertebrates, while invertebrates and plants lack orthologs to 
many of the targets. The presented predictions can serve as a basis for identifying 
potentially sensitive (and insensitive) species that are used for the environmental 
risk assessment of pharmaceuticals.  
The effects on fish of exposure to a single pharmaceutical (ethinylestradiol) as 
well as a complex industrial effluent that contains high levels of many drugs were 
explored using microarray analysis. We identified two sensitive and potentially 
robust biomarkers of estrogen exposure by performing a meta-analysis that 
combined our results with data from the literature. The identified biomarkers were 
also used to evaluate the ability of different sewage treatment technologies to 
remove estrogenic substances. Several treatment technologies reduced the levels of 
estrogenic substances, but ozonation was required to remove all measured 
biological effects. The fish that were exposed to a high dilution of the industrial 
effluent showed increased hepatic Cyp1a enzyme activity and altered expression of 
several genes that are involved in the detoxification of chemicals and drugs. 
Although the gene expression pattern did not clearly point to any specific group of 
substances, it could serve as a basis for hypothesizing mechanisms of toxicity and 
possible causative agents in the effluent.  
More research is needed to understand the risks of residual drugs in the 
environment, and the presented results show that genomic approaches are useful for 
this purpose.  
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POPULÄRVETENSKAPLIG SAMMANFATTNING
Många av de läkemedel vi tar bryts inte ner fullständigt av våra kroppar. Istället 
transporteras resterna genom reningsverken och hamnar slutligen i våra sjöar och 
vattendrag. Låga koncentrationer av flera olika läkemedel har hittats i miljön, men 
vi vet väldigt lite om vilka effekter de har på djur- och växtliv. Det finns dock en 
risk att djur och växter kan påverkas av läkemedelsresterna  
Målet med denna avhandling har dels varit att plocka fram data som kan 
förbättra regelverket kring miljöriskbedömningen av läkemedel, dels utveckla 
verktyg som kan öka möjligheterna att upptäcka miljöeffekter av läkemedel. För att 
göra detta har vi använt olika storskaliga molekylärbiologiska metoder.  
Läkemedel är ett viktigt verktyg inom sjukvården som används för att 
förebygga, lindra och bota olika sjukdomstillstånd. Ett läkemedel är designat eller 
utvalt för att specifikt kunna påverka ett visst biologiskt system och samtidigt 
minimera påverkan på kroppens andra funktioner. Lite förenklat kan man säga att 
läkemedel binder och påverkar främst den målmolekyl, till exempel en receptor 
eller ett enzym, som har den funktion i kroppen som läkemedlet är designat att 
påverka. Läkemedelssubstanser är i många fall mycket kraftfulla ämnen. Det 
behövs endast en låg koncentration av läkemedlet för att dess målmolekyl ska 
påverkas. Detta innebär att djur som har målmolekyler som liknar våra löper en 
större risk att påverkas av de låga koncentrationer av läkemedelsrester som hittas i 
miljön. Det är exempelvis känt att det syntetiska östrogenet i p-piller binder till 
östrogenreceptorn i fisk. Det kan leda till att reproduktionen hos fisk påverkas redan 
vid väldigt låga koncentrationer av det syntetiska östrogenet i vattendrag.  
I den första artikeln i den här avhandlingen har vi kartlagt vilka grupper av 
organismer som har målmolekyler som är lika människans. På så sätt har vi kunnat 
se vilka organismer som det är troligt att läkemedelsresterna påverkar. Fisk och 
groda har en motsvarande molekyl till 80% av de 1318 undersökta målmolekylerna. 
Vattenloppan saknade däremot målmolekyler till många läkemedel och algen 
saknade i stort sett målmolekyler till alla läkemedel. Idag görs dock mycket av 
miljörisk-bedömningen av läkemedel inte på fisk, utan på ryggradslösa djur, såsom 
vattenloppor eller på alger eller växter. Vår studie visar att vattenloppan i många 
fall inte är representativt som försöksdjur för miljöriskbedömning av humana 
läkemedel. Baserat på våra resultat föreslår vi att miljöriskbedömningen av humana 
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läkemedel i högre grad bör baseras på försök med fisk eller groda. Kartläggningen 
av målmolekyler kan också användas som en guide för att avgöra om det är relevant 
att använda andra organismer än fisk och groda för en miljöriskbedömning av ett 
läkemedel. 
I de andra tre studierna som den här avhandlingen bygger på har vi tittat på hur 
läkemedel kan påverka genuttrycksmönstret i levern hos fisk. Genuttrycksmönstret 
förändras hela tiden hos alla organismer som ett svar på att miljön förändras. 
Vardagliga förändringar så som dag/natt eller kallt/varmt påverkar genuttrycket, 
men en exponering för en kemikalie, exempelvis ett läkemedel, leder i många fall 
också till genuttrycksförändringar. Ett förändrat genuttryck är alltså inget negativt i 
sig självt. Genom att studera uttrycket hos flera tusentals gener samtidigt så kan vi 
få en förståelse för vilka biologiska processer som satts igång i fisk som exponerats 
för ett läkemedel. Vi kan också få indikationer på om förändringarna i genuttryck 
innebär något negativt för fisken. Metoden som vi har använt kallas microarray eller 
gen-chip-analys och med den kan vi mäta uttrycket av tiotusentals gener samtidigt.  
Tidigare studier har visat att det renade avloppsvattnet från reningsverk kan 
innehålla tillräckligt höga koncentrationer av östrogena ämnen för att feminisera 
hanfisk och på så sätt störa reproduktionen. Det syntetiska östrogenet i p-piller är en 
substans som starkt bidrar till att hanfiskar blir feminiserade. Vår målsättning med 
den andra studien artikel nummer två var att hitta förändringar i genuttryck som kan 
användas för att visa att hanfisk utsatts för östrogena ämnen. Regnbågslax 
exponerades för antingen en hög eller en låg koncentration av det syntetiska 
östrogenet och vi analyserade fiskens genuttrycksmönster med microarrayer. Vi 
identifierade två genuttrycks-markörer som kan användas för att visa att hanfisk 
utsatts för östrogena ämnen. Markörerna använde vi sedan i den tredje studien för 
att utvärdera hur bra olika reningsverkstekniker är på att ta bort östrogena ämnen 
från avloppsvatten. Det ingående avloppsvattnet till ett kommunalt reningsverk 
renades med sex olika parallella tekniker och fisk exponerades för samtliga renade 
vattnen. Alla de testade reningsverksteknikerna minskade koncentrationerna av 
östrogena ämnen, men för att ta bort alla de analyserade effekterna i fisken krävdes 
en avancerad teknik, ozonering. 
I den fjärde studien använde vi microarraymetoden för att studera vilka 
biologiska processer som påverkas hos fisk som exponerats för ett avloppsvatten 
från läkemedelsindustrier. Tidigare har vår forskargrupp visat att ett reningsverk 
som tar hand om processvatten från 90 olika läkemedelsindustrier i Patancheru, 
Indien, släpper ut mycket höga nivåer av läkemedel. Ett annat försök visade att 
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vattnet från reningsverket påverkar grodors tillväxt redan vid stor utspädning. 
Genom att exponera fisk för samma spädning av avloppsvattnet som i det 
ovannämnda grodförsöket kunde vi visa på att många biologiska processer som 
bryter ner läkemedel och andra kemikalier hade startats i fiskens lever. Fisken hade 
också förhöjda nivåer av fosfat och kolesterol i blodet. En förhöjd fosfatnivå i 
blodet hos människa kan betyda att njuren sviktar. Däremot kunde vi inom ramen 
för denna studie inte identifiera vilka grupper av läkemedel eller andra kemikalier 
som orsakar vattnets giftighet, då de vatten som fisken exponerades för innehåller 
tusentals olika substanser. Våra resultat kan dock utgöra en grund för fortsatt 
forskning inom området och det är viktigt att vi får reda på om och i så fall hur de 
höga koncentrationerna av läkemedelsrester kan påverka djur, växter och även 
människor. Många av de läkemedelsubstanser som tillverkas i Patancheru i Indien 
används i produkter som säljs över hela värden, inklusive Sverige. Ansvaret för att 
föroreningssituationen i det här området förbättras är därför också global. 
Sammanfattningsvis är kunskap om vilka risker som finns med läkemedel som 
släpps ut i vattendrag och sjöar begränsad. I den här avhandlingen har vi visat att 
storskaliga molekylärbiologiska metoder kan hjälpa till att fylla de kunskapsluckor 
som finns, som i sin tur kan leda till förbättrat regelverk kring 
miljöriskbedömningen av läkemedel. 
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A note on gene and protein nomenclature 
Throughout the thesis the rainbow trout (Oncorhynchus mykiss) genes are named 
according to the ZFIN zebrafish nomenclature, i.e. the gene symbols of the ortholog 
gene in zebrafish have been used. Gene symbols are three or more lowercase letters and 
are in italics and correspond to the human gene name in cases of established orthology 
between zebrafish and human. The protein symbol is the same as the gene symbol, but 
non-italic and the first letter is uppercase. Human genes and proteins are named 
according to their official HGNC symbol, three or more uppercase letters that are 
italicized when referring to the gene. 
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1. INTRODUCTION
Pharmaceuticals are vital tools for preventing, treating or mitigating diseases, 
and, as such, medicines greatly contribute to the well-being of humans. 
Unfortunately, active pharmaceutical ingredients (APIs) can also become 
environmental pollutants if they reach the environment. Pharmaceuticals are 
specifically designed or selected to have a potent biological action and to not be too 
easily degraded. They are, in most cases, also able to cross cell membranes. 
Furthermore, the specific molecular targets of a drug can be well conserved in 
wildlife species, which may result in pharmaceuticals becoming potential 
environmental hazards, even at low concentrations. The extensive use of drugs in 
human and veterinary medicine is steadily increasing, and awareness of the 
presence and effects of pharmaceuticals in the environment has been growing since 
the mid 1990s. 
1.1. Occurrence and emission routes 
More than 150 APIs have been detected in the environment, and monitoring 
studies have demonstrated the presence of pharmaceutical residues in treated waste 
water and surface water in Sweden (Bendz et al., 2005; Zorita et al., 2009), in 
Europe (Thomas and Hilton, 2004; Wiegel et al., 2004; Zuccato et al., 2006), in 
North America (Kolpin et al., 2002) and elsewhere (for reviews, see Heberer (2002) 
and Kümmerer (2008)). Pharmaceutical residues are typically detected at ng/L to 
low μg/L concentrations in treated effluents and surface waters downstream from 
sewage treatment plants (STP). The objectives for municipal STPs are, for example, 
to remove organic substances, phosphorus and nitrogen. They are not, however, 
designed to remove pharmaceuticals, even if many APIs happen to be degraded or 
separated from the effluent by the treatment processes. There is great variability in 
the removal efficiency, which depends both upon the STP and the drug (Kümmerer, 
2008). Certain drugs, such as ibuprofen and salicylic acid, are easily degraded and 
commonly have removal rates above 95%, while carbamazepine and diclofenac are 
considerably more persistent, with the great majority passing the treatment plants 
(Joss et al., 2005; Kasprzyk-Hordern et al., 2009). The removal of the synthetic 
estrogen, 17-?-ethinylestradiol (EE2), varies between 64% - 100%, depending on 
the type of STP treatment (Ternes et al., 1999; Muller et al., 2008).  
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Drug residues that originate from human use end up in sewage effluents as a 
result of excretion and, to some extent, from inappropriate disposal of unused drugs. 
Veterinary drugs, on the other hand, reach the terrestrial or aquatic environment 
through a variety of sources and routes. The manufacture of bulk drugs has recently 
been identified as a point source for the release of extraordinarily high 
concentrations of APIs to the aquatic environment in India and China (Cui et al., 
2006; Larsson et al., 2007; Li et al., 2008). The effluent from a treatment plant, 
which regularly receives process water from about 90 bulk drug manufacturers, 
contains very high levels (up to several mg/L) of a variety of drugs (Larsson et al., 
2007). This treatment plant (Patancheru Environ Tech Ltd, PETL) is located in an 
industrial center just outside Hyderabad, India and the APIs that are produced in 
this area are primarily exported to the world market. Larsson and Fick (2009) 
showed that pharmaceutical products sold on the Swedish market contain APIs that 
are produced in this area. They investigated the origin of the APIs in all products on 
the Swedish market containing any of nine preselected substances. In 31% of the 
Swedish products, the API originated from manufacturers that regularly send 
wastewater to the PETL treatment plant.  
1.2. Environmental effects 
Today, we know of a few examples where the presence of APIs in the 
environment has been indisputably linked to adverse effects on wildlife species. 
Relevant, chronic toxicity data are currently lacking for most APIs, and the effects 
and risks of the presence of drug residues in the environment are not well 
understood. 
The widely used analgesic and anti-inflammatory drug, diclofenac, and the 
synthetic estrogen in contraceptives, EE2, are two examples of drugs present in the 
environment that have been clearly linked to adverse effects in wildlife species. 
Diclofenac caused a dramatic decline in a vulture population in India and Pakistan 
(Oaks et al., 2004). Diclofenac is both a human and veterinary drug, and it was 
extensively used to treat livestock in India and Pakistan. Vultures are natural 
scavengers that feed on the carcasses of wildlife and domestic livestock. The dead 
vultures showed signs of renal failure, which is a known side effect in mammals 
that are given high doses of diclofenac. Several lines of evidence, including both 
experimental and epidemiological studies, have helped establish the causality 
between diclofenac exposure and the decline in the vulture population in India and 
Pakistan (Oaks et al., 2004; Shultz et al., 2004; Swan et al., 2006; Cuthbert et al., 
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2007; Green et al., 2007). The synthetic estrogen EE2 is thought to strongly 
contribute to the feminization of fish that are found downstream of STPs. In the 
beginning of the 1990s, roaches (Rutilus rutilus) with intersex characters were 
observed close to municipal STPs in England, and caged fish downstream from the 
STPs showed strong signs of exposure to estrogenic compounds (Purdom et al., 
1994). Fractionation of STP effluents suggested that natural estrogens and EE2 were 
the main contributors to the estrogenic activity of STP effluents (Desbrow et al., 
1998), although sewage effluents can contain a number of endocrine disrupting 
compounds, such as the natural hormones 17?-estradiol (E2) and estrone (E1) and 
the industrial phenols nonylphenol, octylphenol and bisphenol A. Since then, many 
studies have been published that provide extensive evidence for a causal link 
between EE2 exposure and feminization of fish in the environment (Routledge et al., 
1998; Larsson et al., 1999; Jobling et al., 2002b; Parrott and Blunt, 2005; Kidd et 
al., 2007).  
There are a few more examples of studies suggesting that pharmaceuticals affect 
aquatic organisms at or around measured environmental concentrations. Laboratory 
experiments with the non-steroidal anti-inflammatory drug (NSAID) diclofenac 
show that it may affect aquatic organisms at environmentally relevant 
concentrations. Diclofenac is frequently detected in at concentrations up to the μg/l-
level in investigations of sewage effluents and surface waters (Heberer, 2002). A 
concentration 1μg/L cause a variety of effects in fish, including cytological 
alterations in the liver, kidney and gills (Schwaiger et al., 2004; Triebskorn et al., 
2004; Hoeger et al., 2005). Neuroactive drugs such as SSRIs have also been 
proposed to affect non-target organisms at environmentally realistic  concentrations 
(De Lange et al., 2006; Kreke and Dietrich, 2008). The fibrate gemfibrozil may also 
pose a risk for aquatic organisms, as a low concentration (1.5μg/L) was reported to 
decrease the circulatory levels of testosterone in goldfish (Carassius auratus) 
(Mimeault et al., 2005).  
The above mentioned studies all describe examples of drugs that primarily are 
designed to interact with human drug-targets. The release of drugs that target 
different parasites and bacteria can also affect wildlife species. For example, 
veterinary parasiticides, such as ivermectin, affect non-pest dung-feeding flies and 
beetles (for reviews, see Lumaret and Errouissi (2002) and Floate (2006)) . 
Ivermectin is also highly toxic to aquatic crustaceans (Garric et al., 2007). The 
release of antibiotics into the environment is also of concern (Larsson et al., 2007). 
Residual antibiotics can potentially affect environmental bacteria, fungi and 
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microalgea, and, even more alarmingly, the presence of antibiotics in surface waters 
might contribute to the spread of antibiotic resistance (Kümmerer, 2008). The issue 
will, however, not be discussed further, since the focus of this thesis has been on 
pharmaceuticals with human drug targets and/or the effects of pharmaceuticals on 
aquatic vertebrates. 
1.3. Environmental risk assessment 
An environmental risk assessment is defined as the procedure by which the 
likely or actual adverse effect of pollutants on ecosystems and their components are 
estimated with a known degree of certainty using scientific methodologies (van der 
Oost et al., 2003). The papers that this thesis is based upon are primarily focused on 
the assessment of effects of pharmaceuticals and to a much lesser extent on the 
exposure. However, the potential implications of our data on gene expression and/or 
conservation of drug targets on the environmental risk assessment of 
pharmaceuticals will be discussed throughout the thesis.  
For about ten years, environmental risk assessments have been compulsory for 
the approval of new pharmaceutical products in the United States and the European 
Union (FDA, 1998; EMEA, 2006; EMEA, 2007). The risk assessment for the 
aquatic environment is, in principal, based upon a predicted exposure concentration 
(PEC) and a predicted no-effect concentration (PNEC). In the USA, the PNEC 
value may be based on acute responses (lethality) only, and no tests on fish are 
mandatory. However, the possible environmental effects of APIs are not expected 
to be acute and general, such as narcosis, but rather more subtle and specific, since 
most APIs act through specific modes of action. In addition, the no-observed effect 
concentration (NOEC) of the acute and chronic responses for the few investigated 
APIs show a very low degree of correlation (EMEA, 2006). Acute toxicity can be 
presented as median lethal concentration (LC50) and measured LC50 values for EE2 
in fish are typically around 1 mg/L. Often an assessment (uncertainty) factor, 
usually 1,000 can be applied to the lowest acute toxicity data when chronic data is 
missing and such a factor is also used to extrapolate results between species. 
However, the PNEC value for chronic toxicity data for EE2 in fish is below 1 ng/L 
which would correspond to an assessment factor of more than a million for the 
acute value to be protective for chronic effects in fish. In 2006, acute tests were 
abandoned from the European risk assessment procedures for human drugs and 
were replaced by chronic toxicity tests with Daphnia and algae and semichronic, 
early life-stage tests with fish (EMEA, 2006). Relevant and comprehensive toxicity 
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data are, however, lacking for APIs that were approved before 2006. Despite the 
new EU guidelines, there is still little focus on targeted test strategies that use the 
known pharmacological properties of the API in the selection of species, tests, and 
endpoints. 
1.4. Comparative pharmacology
The molecular mechanisms behind the uptake, distribution, metabolism, 
excretion and pharmacological effects can be rather well conserved between the 
organism that the API is intended to affect and non-target organisms in the 
environment. Indeed, all environmental effects that have been clearly assigned to 
residual drugs are consistent with high affinity interactions with conserved drug 
targets in the affected wildlife species rather than with a general toxic effect. The 
vast knowledge base that has been derived during the development of a drug in 
humans and other mammalian models can therefore provide a basis for an expanded 
understanding of the potential action of residual pharmaceuticals in exposed 
wildlife species. It has been suggested by several authors that such information can 
be used to develop more efficient test strategies (Seiler, 2002; Ankley et al., 2007; 
Kostich and Lazorchak, 2008).  
The physiochemical, pharmacological and toxicological properties of an API is 
extensively studied during the development of a new drug. For most approved 
pharmaceuticals, these kinds of data are easily accessible in different public 
databases. The most frequently used drug databases in this thesis are listed below:  
? The DrugBank database (http://www.drugbank.ca/) is an example of a 
bioinformatics and chemoinformatics resource that combines detailed drug 
data with metabolizing enzyme and drug target information for the 
majority of all FDA approved drugs.  
? KEGG DRUG (http://www.genome.jp/kegg/drug/) is an information 
resource for all approved drugs in Japan and the USA based upon the 
drugs’ chemical structures. It also contains information about drug targets 
and pathways. 
? The Pharmacogenetic and Pharmacogenomics Knowledge base 
(PharmGKB; http://www.pharmgkb.org/) has information about the 
relationships between drugs, their affected pathways and the genes therein, 
although it contains information on only a few drugs and drug targets. It 
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aims to aid researchers in understanding how genetic variation among 
individuals contributes to differences in their reactions to drugs. 
? RxList (http://www.rxlist.com/script/main/hp.asp) is a comprehensive drug 
information database that aims to assist and support clinical decisions. 
However, to make well-founded predictions, a comprehensive understanding of 
the physiology of the exposed wildlife species is equally important, and this is 
currently a hampering factor for the vast majority of species. A few comparative 
pharmacology reviews that focus on a certain drug and/or a group of species have 
been published. The European Centre for Ecotoxicology and Toxicology of 
Chemicals (ECETOC) has published a review on the use of intelligent test 
strategies in ecotoxicology (ECETOC, 2007). The ECETOC’s review demonstrates 
how information about the mode-of-action for specifically acting chemicals could 
be used in the environmental risk assessment. Many of the examples and case 
studies include pharmaceuticals. Other reviews that have focused on the 
comparative pharmacology in fish for selective serotonin reuptake inhibitors 
(SSRIs) (Kreke and Dietrich, 2008) and adrenoreceptor antagonists (beta-blockers) 
(Owen et al., 2007) have been published. Brain et al. (2008) reviewed the effects 
and risks of exposure to pharmaceuticals in aquatic plants. A number of target sites 
for antibiotic drugs are evolutionarily conserved in plants because their plastid 
organelles have bacterial ancestry. The statin type of blood lipid regulators belongs 
to a group of pharmaceuticals that have a human target, which is also conserved in 
plants. Measurements of the downstream metabolites (sterols) of the target enzyme 
(HMG-CoA reductase) provided a sensitive endpoint in the aquatic plant Lemna 
gibba. Apart from antibiotics and statins, there are few other classes of 
pharmaceuticals that we know exert a strong toxicity in plants. The different 
reviews all conclude that future toxicological testing should encompass and reflect 
the known pharmacological effects of the substances studied and should, therefore, 
focus more strongly on specific molecular targets. 
The number of attempts to perform comparative pharmacology in a large scale 
manner are few (Huggett et al., 2003; Kostich and Lazorchak, 2008). The recent 
advances in DNA sequence analysis, and the characterization of genomes have 
created new possibilities to advance the field of comparative pharmacology with an 
ecotoxicological focus. Information that is gained from deeper comparative efforts 
has the potential to aid in prioritizing which drugs need further attention for 
assessment of their environmental risks, and which organisms could be prioritized 
for testing, and appropriate endpoints.  
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1.5. Genomics
The increasing number of sequencing efforts of environmentally relevant 
species has enabled the use of different genomic approaches in the assessment of 
the environmental risks of pharmaceuticals. 
Since there is no straightforward definition of genomics, the word, in this thesis, 
will be used to illustrate large scale methods to study the genome, its different 
building-blocks and their functions. The mouse geneticist Thomas Roderick is 
believed to have coined the term genomics to describe an approach to study DNA at 
the level of chromosomes, entire genomes or large clusters of genes (McKusick and 
Ruddle, 1987). The purpose was to distinguish traditional genetic methods that 
focused on one gene or a family of related genes from more large scale methods. 
Another common definition of genomics is “the study of genes and their function” 
(Hocquette, 2005). 
There are a multitude of advances that have been made in molecular biology, 
statistics and computer science that led to the term genomics being coined. One 
important step forward was the development of the chain termination method of 
DNA sequencing, also known as the Sanger method (Sanger et al., 1977b). In 1977 
Frederick Sanger used this technique to, for the first time, fully sequence a genome 
(Phage ?-X174) (Sanger et al., 1977a). Since then, there has been rapid progress in 
automated sequencing methods. Today, hundreds of eukaryotic genomes have been 
extensively sequenced (Peregrin-Alvarez and Parkinson, 2007) (http://genome.jgi-
psf.org/euk_home.html and http://www.ensembl.org/index.html), and the majority 
of the sequenced vertebrate species are mammals (http://www.ncbi.nlm.nih.gov/ 
genomes/static/gpstat.html). The sequencing efforts for species that represent more 
ecotoxicologically relevant taxonomic groups were, until very recently, rather few. 
However, in the last few years, several environmentally relevant species have 
become fully sequenced, including the green alga (Chlamydomonas reinhardtii) 
(Merchant et al., 2007), the water flea (Daphnia pulex) (http://genome.jgi-
psf.org/Dappu1/Dappu1.home.html) and the stickleback (Gasterosteus aculeatus) 
(http://www.ensembl.org/Gasterosteus_aculeatus/Info/Index), and there are 
numerous additional, extensive EST libraries that are available for other species, 
such as the rainbow trout (Oncorhynchus mykiss) (http://compbio.dfci.harvard. 
edu/tgi/). This has opened up new possibilities to perform microarray analysis and 
large scale bioinformatic comparisons to assess the environmental risks of 
pharmaceuticals. 
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1.5.1. DNA Microarrays 
The modes of action for many APIs in mammalian species are well known, and 
this information could be used to create hypotheses of potential effects in wildlife 
species. However, interactions with unexpected targets are possible, and other 
endpoints, which are different from the mammalian ones, could be more sensitive. 
In addition, even if a drug target is evolutionary well conserved, the target protein 
might have different biological functions in different organisms. Microarrays 
provide an efficient tool to study thousands of potential gene responses 
simultaneously and thus may be used to find sensitive responses to an exposure as 
well as information about the mode of action. 
DNA microarray technology was introduced in the mid 1990s. The first use of a 
spotted cDNA array was published in 1995 (Schena et al., 1995), and the first use of 
an oligonucleotide array was published in 1997 (Wodicka et al., 1997). In 1999, the 
journal Nature Genetics dedicated a whole supplement to this up and coming 
technology (Cohen, 1999). Since then, microarrays have been successfully applied 
to various areas within biology, such as the categorization of cell cycle genes in 
yeast (Spellman et al., 1998), the classification of breast cancer (Sorlie et al., 2001) 
and toxicant profiling (Waring et al., 2002).  
 Several commercial array platforms are available through companies such as 
Affymetrix (http://www.affymetrix.com) and Agilent (http://www.agilent.com). 
The strengths of commercial platforms are their readymade protocols and support, 
as well as their overall high quality. Few commercial array platforms are, however, 
available for environmentally relevant species. Non-commercial arrays have been 
developed by academia, such as a small spotted cDNA array for the European 
flounder (Platichthus flesus) (Williams et al., 2003), different cDNA arrays for 
salmonid species (Rise et al., 2004; von Schalburg et al., 2005), a cDNA array for 
Daphnia magna (Soetaert et al., 2006), an oligonucleotide microarray for the 
fathead minnow (Pimephales promelas) (Larkin et al., 2007) and an oligonucleotide 
microarray for the eelpout (Zoarces viviparus) (Kristiansson et al., 2009a). The 
usage of microarrays to generate or test an ecotoxicological hypothesis is a rather 
new concept, as shown in Figure 1.  
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Figure 1. The number of articles with the different topic words ecotoxicology, microarray, or 
ecotoxicology and microarray that are present in the Science Citation Index Expanded (SCI-
EXPANDED) database at the ISI Web of Science.  
 
Several articles that describe the potential of integrating genomics and 
microarrays into ecotoxicology have been published (Snape et al., 2004; Ankley et 
al., 2006; Ju et al., 2006; Lettieri, 2006; Steinberg et al., 2008). A microarray 
analysis could assist in the identification of potential biomarkers of exposure or 
effect and increase the understanding of the (toxicological) mode of action of 
chemicals or mixtures. Microarray analysis could also be used to categorize 
individual chemicals and mixtures into different classes for their modes of action. 
Furthermore, the obtained gene response patterns might aid in the identification of 
substances that are responsible for the toxic effects that are caused by a mixture.  
1.6. Biomarkers 
A biomarker can be defined as “a biological response to a chemical or 
chemicals which gives a measure of exposure and sometimes, also, of toxic effect” 
(Peakall and Walker, 1994). The biological response can range from molecular to 
cellular and physiological responses and to behavioral changes. According to WHO 
(1993), biomarkers can be subdivided into three classes, which are the biomarkers 
of exposure, effect and susceptibility. The definitions of biomarkers of exposure 
and effect are not clearly separated. Biomarkers of exposure can be used to confirm 
and assess the exposure to a particular substance or to a group of substances. 
Biomarkers of effect can be used to document either activational, reversible 
alterations or more permanent adverse effects. This could become important when 
relevant chemical measurements cannot be achieved or full life cycle tests are not 
feasible. Biomarkers of susceptibility can be genetic differences that can explain 
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variations in the degree of response to toxicant exposure that are observed between 
different individuals or species (see section 4.1.1.).  
The induction of vitellogenin mRNA (vtg) or protein (Vtg) in male and juvenile fish 
has been established as a commonly used biomarker for estrogen exposure. Vtg is a 
precursor of yolk proteins in oviparous vertebrates. It is usually produced in the 
liver of sexually maturing female fish and transported to the ovaries via the 
circulation. Endogenous estrogen regulates its expression and it is normally not 
expressed in male or juvenile fish. However, Vtg can be induced in male and 
juvenile fish if they are exposed to estrogen or estrogen-like chemicals (Sumpter 
and Jobling, 1995). The discovery that EE2 is an important contributor to the 
endocrine disruption that is observed in fish downstream from municipal STPs was 
greatly facilitated by the use of Vtg as a biomarker (Purdom et al., 1994; Sumpter 
and Jobling, 1995; Desbrow et al., 1998; Routledge et al., 1998; Larsson et al., 
1999; Jobling et al., 2002b). However, it has been shown that estrogens can have an 
organizational, permanent effect, such as on gonadal sex differentiation, at a 
concentration that is not sufficient to give rise to a measurable Vtg response (Örn et 
al., 2003). The induction of zona radiata proteins has been suggested to be more 
sensitive biomarkers of estrogen exposure (Thomas-Jones et al., 2003), but their 
specificity for estrogens is not as clear (Larsson et al., 2002; Berg et al., 2004).  
In paper II, III and IV, we have focused on the identification of gene expression 
changes that can be used as biomarkers of exposure and/or effect. Good biomarkers 
are sensitive, and the response should preferably also correlate with the magnitude 
of the exposure. It is also desirable that the biomarker is specific for the substance 
or group of substances of concern (or the adverse effect of concern). Likewise, it 
should preferably be robust when considering both different exposure scenarios and 
different measuring techniques. The regulation of a single gene rarely fulfills all the 
above mentioned criteria, but a combination of responses could together potentially 
increase the degree of evidence. 
Sometimes the questions are complicated and the answers are simple 
Dr.Seuss 
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2. SCIENTIFIC AIMS
There is growing concern about the environmental effects of pharmaceuticals. 
Many different APIs are detected in the environment, but their effects are not well 
understood. We have addressed this issue by using experimental and computational 
genomics techniques. 
 
The aims of this thesis have been:  
? To investigate and exemplify how the use of available mammalian 
pharmacological data can aid in the assessment of ecotoxicological risks 
that are posed by pharmaceuticals. 
 
? To explore how exposure to a single pharmaceutical, as well as exposure to 
a complex mixture of APIs and other chemicals, affects the global hepatic 
gene expression pattern in fish, with a special focus on the identification of 
biomarkers of exposure.  
 
? To evaluate the abilities of different sewage treatment technologies to 
reduce estrogenic substances and gene expression changes in exposed fish.
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3. METHODOLOGICAL CONSIDERATIONS
3.1. Fish exposures 
All exposure experiments that are described in this thesis were performed with 
farmed rainbow trout under controlled laboratory conditions. Rainbow trout is a 
salmonid species, the basic physiology of which is rather well understood. An 
extensive expressed sequence tag (EST) library for this species is also available at 
the DFCI rainbow trout gene index database (http://compbio.dfci.harvard.edu/tgi/). 
Trout is easily obtained and thrives well in both laboratory conditions and in 
Swedish fresh water. Our group often exposes rainbow trout in the field to various 
contaminant sources (e.g., caged in a river), and it was important that microarrays 
were developed for a species that would tolerate Swedish waters and temperatures.  
The abundance of thousands of mRNAs can be simultaneously measured in a 
microarray experiment but the number of biological replicates is usually small (less 
than 10) due to the relatively high costs of the analyses. The identification of genes 
with an altered expression due to differences in exposure is therefore particularly 
sensitive to both technical and biological variation. Controlled laboratory 
experiments, with well-acclimatized farmed fish that were not fed during the 
exposure, are examples of the efforts that were taken in order to minimize the 
biological differences between individuals and aquaria. Rainbow trout cope well 
without food for two weeks, and longer exposure time periods allow chemicals to 
bioconcentrate and approach a steady state between the concentrations in the fish 
and the water. In papers II and III, the fish were exposed in a flow-through system 
for two weeks. In paper IV, the fish were exposed for five days due to a limited 
amount of effluent.  
The liver was used for gene expression analysis in all three studies. The liver is 
the major detoxifying organ and many pharmaceuticals, including EE2, affects the 
hepatic gene expression pattern. Effects on mRNA abundance in several organs, at 
different time points and at different exposure concentrations would have given a 
more comprehensive picture but such studies were economically not feasible. In 
paper II, the aim was to find sensitive responses and therefore we exposed the fish 
to a low, environmentally relevant concentration and a high concentration. The high 
concentration facilitated the identification of the more subtle responses that were 
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induced by the low concentration. In paper IV the aim was to increase the 
understanding of the effluent’s toxicological mode(s) of action. A previous study 
had shown that 0.2% of the effluent strongly reduced the growth of tadpoles 
(Carlsson et al., 2009). This dilution was therefore used and the limited amount of 
effluent decided the duration of the exposure.  
3.2. Sequence analysis and annotation assignment 
As mentioned above, an extensive EST library is available for rainbow trout, but 
relatively few genes are fully sequenced and characterized in trout. The transcripts, 
ESTs and corresponding probes that were used in this thesis have been functionally 
annotated using different automated methods for sequence analysis. The basic local 
alignment search tool (BLAST) (Altschul et al., 1997) is a method to search and 
compare protein and DNA sequences against query databases i.e. BLAST searches 
for subsequences in a database that match subsequences of the query 
transcript/protein by optimizing a local similarity measure. Functionally similar 
genes and proteins can be linked by identifying the best BLAST hit with an E-value 
cut-off. ESTs are typically annotated using a tblastx (comparison of a translated 
nucleic acid query versus a translated nucleic acid database) with a non-stringent E-
value cut-off, such as 10-5. This was the approach that was taken to annotate the 
transcripts of the probes on the array that was used in paper IV. Different BLAST 
strategies were also used in paper II, both to cluster the ESTs that were available on 
the salmonid cDNA microarray and to link functionally similar genes between the 
different species that were used in the meta-analysis.  
3.2.1. Ortholog prediction 
In paper I, a more sophisticated BLAST-based method was used to predict 
functionally similar proteins between species. One way to link functionally similar 
proteins is to look at the evolutionary relationship between proteins. Homologous 
proteins share a common ancestry and can be further characterized as orthologs or 
paralogs (Figure 2). Orthologs are homologous proteins that exist in different 
species as a result of speciation. Orthologous proteins in different species generally, 
but not necessarily, retain the same function. Paralogs, on the other hand, originate 
from gene duplication events within a genome and can be further divided into in-
paralogs and out-paralogs, depending on whether the duplication event occurred 
before or after a speciation event. Although paralogous proteins often retain similar 
biochemical functions, they generally diverge after the duplication event.  
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Figure 2. Homologous proteins have a shared common ancestry. In (a), an ancestral gene G 
undergoes one speciation event, which is followed by a gene duplication event in human. The 
different variants of G that appear in human and frog are called orthologs (G frog and G1 or G2 
human). The different variants within each species are called paralogs. Paralogs that appear as a 
result of a gene duplication event that occurred after the latest speciation event are called recent or 
in-paralogs (G1 human and G2 human). In (b), the ancestral gene G undergoes one gene duplication 
event followed by two speciation events. The different variants (G1 frog, G1 human and G1 rat) are 
referred to as orthologs while; for example, G1 frog and G2 rat are not orthologs. The paralogs in (b) 
are called ancient or out-paralogs. 
 
There are many different computational approaches to identify homologous 
proteins between organisms, but two basic schemes underlie these different 
approaches: phylogenetic analysis and BLAST-based methods. Phylogenetics is the 
study of evolutionary relatedness based upon molecular sequence data. A 
phylogenetic analysis is a computational approach that uses phylogenetic trees to 
infer groups of orthologous proteins. To build phylogenetic trees, high quality 
multiple sequence alignments are usually required, and the methods are often 
computationally expensive and generally seem to also require manual intervention 
(Dolinski and Botstein, 2007). 
BLAST-based approaches require much less computation and allow for full 
automation. In its simplest form, a one-way BLAST is performed, and a sequence 
similarity above a pre-defined threshold defines two proteins as orthologs. For 
example, a BLASTp is performed for a query protein against a protein database, 
such as Uniprot (http://www.uniprot.org/). However, one-way sequence 
comparisons often create many false positives. Chen et al. (2007) showed that a 
one-way BLAST strategy can have as much as 50% false positives and 4% false 
negatives in their assignment of the performance of different orthology detection 
strategies. The one-way BLAST method cannot distinguish between in-paralogs 
and out-paralogs and assigns them inappropriately as ortholog pairs, which leads to 
many false positives. In contrast, a reciprocal best BLAST hit strategy displays few 
false positives (estimated at 8%),  but many false negatives (estimated at 30%) 
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(Chen et al., 2007). This strategy cannot recognize many-to-many or many-to-one 
ortholog relationships, which results in a high false negative error rate. Despite this 
problem, it is often suitable as a first step for advanced BLAST-based ortholog 
detection methods.  
 
Figure 3. Identification of both paralogs and orthologs is necessary to understand the evolutionary 
history of a gene. The figure shows an example of an ancestral gene G, which appears as only one 
gene in frog, while rat has two in-paralogous genes and human has three. Since the reciprocal best 
BLAST hit (RBH) of G1 in frog is G1 in human and G2 in rat, while the RBH of G1 in human is G1 in 
rat, algorithms that solely use information from the RBHs would not identify orthologs for G in all 
three species. However, the clustering approach utilized by OrthoMCL can detect all these non-
trivial relationships and correctly assign all variants within a single cluster that contains both the in-
paralogs and the orthologs. 
The OrthoMCL algorithm (Li et al., 2003), which was used in paper I, is an 
example of a BLAST-based method that aims to separate the in-paralogs from the 
out-paralogs. The OrthoMCL algorithm distinguishes between the two types of 
paralogs by first using all-against-all BLAST comparisons, both within and between 
species. The result is interpreted as a graph where the proteins are nodes and the 
weighted edges are their sequence similarity. This graph is then partitioned into 
sub-graphs using the Markov Cluster (MCL) algorithm (Enright et al., 2002). In the 
final result, the ortholog groups contain only those paralogs that are more similar to 
each other than to any other sequence from the other species. The algorithm was 
estimated to perform well (16% false positives and 7% false negatives) on a 
divergent set of eukaryotic species (Chen et al., 2007).  
There are other methods and considerations that can further improve the 
accuracy of orthology predictions. For example, considerations of synteny, which 
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are the evolutionarily preserved chromosomal positions of genes, can be added to 
the predictions in order to further improve the approach. The NCBI Homologene 
database (http://www.ncbi.nlm.nih.gov/homologene) combines BLAST-based 
sequence similarity measurements with synteny information. For comprehensive 
reviews of existing approaches for ortholog prediction, please refer to Chen et al. 
(2007) and Dolinski and Botstein (2007).  
3.2.2. Functional annotation and characterization of genes  
Different bioinformatic resources that aim to aid in the biological analysis of 
microarray data are available. In papers I and IV, Gene Ontology (GO) (Ashburner 
et al., 2000; The Gene Ontology Consortium, 2008) analysis was used. The GO 
project is a collaborative effort for the controlled and consistent description of 
protein attributes. GO has three main ontologies that describe molecular functions, 
biological processes and cellular components. The GO project is an important 
resource that describes proteins in a systematic way, but the management and 
merging of ontologies (e.g., between species) is a complex task and an ongoing 
research area.  
Pathway analysis is another method that can be used to understand and interpret 
gene expression data. Many proteins in mammalian model species have been 
associated with one or more pathways, and there are several ongoing efforts to 
systematically characterize pathways, such as the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) (Kanehisa et al., 2008). 
 Both pathway and GO analysis can be performed in order to test whether genes 
from a given pathway or genes with a certain GO term have higher tendency to be 
differentially expressed than other genes on a microarray. The procedure is usually 
repeated for all pathways or GO terms in a database, and the models best describing 
the gene expression pattern can thus be identified. In paper IV, different top lists of 
the most significantly regulated genes were analyzed for overrepresentation of GO 
terms and KEGG pathways.  
Few rainbow trout proteins have GO annotations assigned to them, and, 
therefore, GO annotations that have been assigned to orthologous proteins in 
reference species need to be used instead. For example, the estrogen receptor in 
rainbow trout does not have any GO assignments in the database AmiGO 
(http://amigo.geneontology.org/cgi-bin/amigo/go.cgi), but the human estrogen 
receptor 1 (ESR1) has 11 GO term associations, which include four biological 
process terms (GO:0030520: estrogen receptor signaling pathway, GO:0048386: 
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positive regulation of retinoic acid receptor signaling pathway, GO:0006355: 
regulation of transcription and DNA-dependent, GO:0007165: signal transduction). 
On the other hand, the zebrafish (Danio rerio) Esr1 has only three GO term 
associations, which, are all biological process terms (GO:0042221: response to 
chemical stimulus, GO:0043627: response to estrogen stimulus and GO:0009410: 
response to xenobiotic stimulus). To my knowledge, all the biological process terms 
mentioned above describe the estrogen receptor 1 both in humans and in zebrafish, 
but the discrepancy between the annotations implies that the output from a rainbow 
trout GO term analysis will heavily depend on the chosen reference species. 
Since rather few proteins have been functionally characterized in rainbow trout 
(181 reviewed proteins at http://www.uniprot.org/), the function of the majority of 
the proteins is described via high sequence similarities to proteins that have been 
characterized in other species. There are many challenges in the correct assignment 
of orthologous proteins in divergent species, and, even if the assignment is correct 
from an evolutionary perspective, their functions might still differ. Another 
weakness with automated annotations is that genes are annotated according to 
already discovered functions. Accordingly, biological processes that are implicated 
in a microarray experiment seem to confirm the functions of proteins and are 
seldom used to discover new pathways or protein functions. 
3.3. DNA microarray experiments 
3.3.1. General 
The microarray technology enables measurement of the abundance of several 
thousands of transcripts simultaneously. Simplified, total RNA is isolated from the 
animal/tissues/cells of interest, and the mRNA in the sample is converted into 
fluorescently-labeled complementary DNA (cDNA) or a type of modified amplified 
RNA (aRNA). A hybridization solution, which contains the cDNA, is then 
incubated on a surface, such as a glass slide, that contains thousands of regularly 
spaced probes. Finally, the unbound cDNA is washed away, and the amount of 
hybridized cDNA is visualized, typically by a laser scanner or a CCD camera 
(Figure 4). The spots containing the different probes are localized, and intensity 
data are extracted from the fluorescent images with software for image analysis (for 
this purpose, ImaGene (http://www.biodiscovery.com/index/imagene) was used in 
paper II and Geniom Wizard (http://www.febit.com/go/en/products/geniom-rt-
analyzer) in paper IV). 
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Several technological variants of microarray chips exist, and the probes can be 
of different length and origin. A microarray that uses cDNAs as probes is typically 
created by spotting amplified clones, which are a few hundred nucleotides long, 
from cDNA libraries onto a glass slide. On a spotted cDNA microarray, neither the 
length of the probe sequence nor the amount of signal per transcript is standardized. 
Oligonucleotide arrays, on the other hand, contain probes that are either synthesized 
from the ground up while attached to a surface, such as those produced by 
Affymetrix and febit, or pre-synthesized and then spotted onto a glass slide. The 
oligonucleotide probes are typically between 25 and 70 bases long, and the design 
is done in silico. Spotted microarrays are typically of the two-channel type, in 
which the cDNA from two samples are labeled differently and hybridized to the 
same array, while in situ synthesized arrays are of the one-channel type. In general, 
the results from oligonucleotide arrays compare more favorably to qPCR results 
than the results from cDNA microarrays (Woo et al., 2004; Kuo et al., 2006). 
Exposed fish < control fish
Fluorescence
A. RNA isolation
Control fishB. cDNA synthesis and labeling
C. Hybridization
D. Scanning and analysis of the data
Exposed fish = control fish
Exposed fish > control fish
Gene expression
Exposed fish
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Figure 4.  The principle of microarray analysis for spotted cDNA microarrays, and the experimental 
set-up used in paper II. Total RNA was isolated from control and exposed fish, cDNA was 
synthesized and labeled with the different fluorescent dyes cyanine 3 (Cy3) and 5 (Cy5). Differently 
labeled cDNA from one control fish and one exposed fish was hybridized to the same microarray. 
See also the left microarray picture on the cover of the thesis. 
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3.3.2. The 16k salmonid cDNA microarray
The spotted cDNA microarray used in paper II was developed by a Canadian 
research group belonging to the Consortium for Genomic Research on All Salmon 
Project (GRASP) (von Schalburg et al., 2005). The array contained 16,006 cDNAs 
from EST libraries that were sequenced from different tissues from the Atlantic 
salmon (Salmon salar) and the rainbow trout, in addition to a few cDNAs from 
other salmonid species. The long probes (~400 base pairs) allow some cross 
hybridization to occur which enables cross species usage. The principle of the 
microarray experiment in paper I is shown in Figure 4.  
When the GRASP microarrays were purchased in 2004, the Canadian group had 
just started to re-evaluate its cDNA synthesis kit and hybridization strategy and, 
therefore, did not have any protocol to recommend. We decided to use Invitrogen’s 
SuperScript Indirect cDNA labeling System kit for cDNA synthesis and labeling 
and tried out different hybridization buffers and wash protocols. No matter how 
stringent the hybridization buffer or protocol was, we were not able to solve 
problems with apparent cross hybridization (low specificity). The later addition of a 
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Figure 5.  MA plots showing normalized data from microarray experiments with fish exposed to a 
high concentration of 17-?-ethinylestradiol (EE2) (R) and control fish (G). The log ratios (M = 
log2R/G) are plotted on the y axis against the log of the geometric mean of the signal strength (A = 
(log2R+ log2G)/2) for each spot on the chip. a) Data from a non-stringent hybridization where LNA 
dT blocker has not been added to the hybridization buffer are compared to b) data from the 
optimized hybridization protocol used in paper II. Vtg is expected to be up-regulated several 
hundredfold in the EE2 exposed fish. The absolute fold regulation of vtg is roughly 4 in plot a, while it 
is almost 60 in plot b. Notice also the differences in A values between the two plots. Many of the 
transcripts that are represented on the GRASP array are not expected to be expressed in liver 
tissue, therefore, their corresponding cDNA spot should have an A-value below 8. 
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locked nucleic acid (LNA) dT blocker to the hybridization buffer was found to be 
absolutely crucial for a stringent hybridization (Figure 5). The LNA dT blocker is 
designed to block poly (dA) sequences that are present in the cDNAs spotted on the 
array and prevent them from hybridizing to poly (dT) segments of the labeled 
targets. With the optimized hybridization protocol, several sensitive estrogen 
responsive genes could be identified in paper II.  
Nevertheless, we were not completely satisfied with the platform for several 
reasons. The labeling and hybridization methods typically used for spotted cDNA 
microarrays in general are long and labor intensive and, therefore, easily 
accumulate a high technical variability. In addition, the selection of the ESTs for the 
microarray was not entirely satisfactory. There were also major problems with the 
red channel (Cy5) during the late spring and summer of 2005 and 2006. The signal 
to background ratio was usually above four in both the red (Cy5) and green (Cy3) 
channel on our scanned microarrays. However, in May 2006, the signal to 
background ratio in the red channel decreased below three. One reason for this 
might have been environmental ozone that rapidly can degrade Cy5 while Cy3 is 
much less affected (Fare et al., 2003; Branham et al., 2007). The level of 
tropospheric ozone, which is generated from car exhaust and factory emissions that 
are exposed to sunlight (http://www.naturvardsverket.se/sv/Tillstandet-i-
miljon/Luftkvalitet/Marknara-ozon/), increases during spring and summer in 
Sweden, since high temperatures increase its generation. The highest ozone levels 
are usually measured during the afternoon on warm spring and early summer days, 
and the measured levels in Gothenburg during May 2006 (> 40ppb) were well 
above the levels shown to degrade Cy5 (Fare et al., 2003; Branham et al., 2007).  
Regardless of the problem with Cy5, spotted cDNA arrays in general show less 
agreement with quantitative PCR data compared to oligo-based arrays (Woo et al., 
2004; Kuo et al., 2006). During the autumn of 2006, we had the opportunity to start 
using the highly flexible oligonucleotide-based platform Geniom (Baum et al., 
2003) from febit (www.febit.com) with in situ synthesized probes and several 
automated steps in the hybridization and washing process. 
3.3.3. The Geniom oligonucleotide microarray 
Geniom opened up new possibilities to determine which transcripts and probes 
to put on the array and to also create microarrays for different species. The technical 
variability could be reduced, and the probe design could be optimized.  
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We started with an evaluation project using febit’s own probe design (25bases) 
and recommended hybridization and washing conditions. The expression levels of 
hepatic estrogen-regulated genes were compared between female pools and male 
pools of zebrafish, in which the regulation of six genes was measured by 
quantitative PCR (qPCR). The obtained microarray data unfortunately had low 
consistency with the qPCR data. Therefore, we implemented our own probe design 
procedure. We also had the opportunity to use pools of total RNA from mouse, in 
which the expression of 165 genes was already characterized by qPCR (Kuo et al., 
2006). These pools had previously also been used to compare gene expression 
measurements across different microarray platforms. With our own probe design 
procedure, using OligoArray 2.1 (Rouillard et al., 2003) and optimized 
hybridization and washing conditions, Geniom performed as well as the best 
commercial platforms (Figure 6). The optimized probe design procedure and 
hybridization and wash conditions were used in paper IV (see also the right 
microarray picture on the cover of the thesis). 
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Figure 6.  Pre-processed microarray data from 11 platforms compared to qPCR results for 165 
genes (Kuo et al., 2006; Kristiansson et al., 2009b). Geniom performs as well as the commercial 
platforms Agilent and Affymetrix. The correlation is calculated according to the Pearson’s measure 
(Kristiansson et al., 2009b).  
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3.3.4. Microarray data processing and analysis 
Microarray data need to be processed and statistically analyzed before a biological 
interpretation of the results can be performed. The intensity data that are obtained 
from the image analysis (see section 3.3.1.) need to be processed in order to remove 
technical artifacts and systematic errors. The processing of microarray data 
typically involves background correction and normalization. Background correction 
removes any intensity that stems from wash residue and/or noise from the scanning 
process. Subtraction is the most commonly used method, where the background is 
simply subtracted from the intensity in the spot. Several background correction 
methods have been compared, and the performance of subtraction was inferior to all 
other methods that were investigated, including using no background correction at 
all (Ritchie et al., 2007). No background correction was performed on the array data 
that were presented in papers II and IV. Next, the data are normalized to enable 
comparison between the intensity signals from different samples. Intensity-
dependent trends due to unequal quantities of labeled cDNA, different efficiencies 
in the labeling process, different properties of the dye and other systematic errors 
and biases can be minimized by applying proper normalization algorithms 
(Kristiansson, 2007). Data from two-channel microarrays (differently labeled 
cDNAs hybridized to the same array) need within-array normalization. In paper I, 
the loess normalization method (Yang et al., 2002) was used for this purpose. Loess 
normalization is the most commonly used within-array normalization method. The 
algorithm fits a robust weighted regression line to the MA-plot, and the M-values 
are then centered around zero. In paper IV, we used a one channel microarray, and 
the quantile-quantile algorithm (Bolstad et al., 2003) was used for normalization.  
Statistical analysis is typically performed to identify regulated genes. The 
moderated t-statistic (Smyth, 2004) was used in both papers II and IV. In a 
microarray analysis, a high number of genes are studied in parallel and generally, 
there are few replicates (less than ten). The estimation of the variance can therefore 
become unreliable and standard statistical methods, such as t-tests, can perform 
inadequately. Thus, different methods moderating the variance have been 
suggested. Today, penalized and moderated methods are preferred when analyzing 
microarray datasets (Kristiansson, 2007; Sjögren et al., 2007). The list of potential 
differentially expressed genes can still contain false positives, since thousands of 
responses are tested simultaneously. The threshold for the p-value is therefore 
commonly corrected, and one popular way is to calculate a false discovery rate 
(FDR) (Dudoit et al., 2003). For example, by setting the FDR to 0.2, the list of 
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potentially regulated genes is estimated to contain no more than 20% false 
positives. However, depending on the downstream analysis, different numbers of 
false positives and, thus, false negatives can be allowed in the input data. If all 
genes on a list were to be considered differentially regulated, few false positives 
should be allowed, while a longer list with more false positives can be used in, for 
example, pathway or GO analysis (also discussed in section 3.2.2.). The pathway or 
GO analysis can accommodate a larger number of false positives, since the “falsely 
regulated genes” are less prone to have the same GO annotation or be involved in 
the same pathway. 
In general, other methods are needed to quantify the real difference of the 
mRNA abundance of genes that are identified as differentially regulated by 
microarray experiments. Cross-hybridization and other artifacts are problematic 
issues which, to date, have not been completely solved. Also, the dynamic range of 
microarrays is small, which requires that other methods needs to be applied if a 
more exact quantification is crucial. In the future, ultra high-throughput sequencing 
methods might replace microarray analysis, although costs need to be significantly 
reduced. Sequencing methods have the advantage of elucidating the more exact 
nucleotide content of the target cDNA sequences, and, with the ultra high-
throughput massively parallel sequencing technology, a vast number of sequence 
reads (several hundreds of thousands of single reads per run) can be generated 
relatively inexpensively (Shendure and Ji, 2008; Kristiansson et al., 2009a).  
3.3.5. Principal limitations of gene expression analysis 
A rather large number of the rainbow trout ESTs are not similar to any known 
proteins and, therefore, do not have any annotation. As mentioned in section 3.2.2, 
the fish genomes are not as extensively studied as the mammalian genomes, and the 
presence of unique genes is plausible. However, poly-adenylated non-coding 
transcripts are expressed at low levels and there is a growing understanding of the 
importance of translational/transcriptional regulation by for example microRNAs 
(Kapranov et al., 2002; Bartel, 2009). This implies that measured differences on a 
microarray might not correspond to differences in levels of protein coding 
transcripts.  
It is also important to point out that differences in the abundance of protein 
coding transcripts do not necessary imply differences in protein levels. In general, 
however, protein expression levels do correlate, if only moderately, with transcript 
abundance (de Hoog and Mann, 2004; Lu et al., 2007).  
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Data from microarray experiments is primarily used for hypothesis generation. 
If the analysis, for example, is performed with the aim to find potential biomarkers, 
the usefulness of the identified biomarker needs to be tested. If the microarray 
analysis is instead performed with the aim to obtain information about 
(toxicological) mode of action, the created hypothesis might need to be validated at 
a higher level of biological organization. Furthermore, the gene expression pattern 
for the same chemical exposure can appear very different depending on the phase of 
the organism’s stress response (alarm, resistance or exhaustion phase) (Steinberg et 
al., 2008). It is, therefore, important to have an experimental design that suits the 
aim of the study.  
3.4. Quantitative PCR 
Quantitative PCR is one of the most sensitive methods for the detection and 
quantification of mRNAs, and it is often used for the validation of microarray data. 
It requires an optimized assay that is characterized by well-designed primers that 
amplify only the desired product, an efficient amplification (95-105% efficiency) 
and good reference gene(s). In papers II and IV, qPCR was used to confirm a subset 
of the microarray results, and, in paper III, the method was used to measure the 
gene expression of estrogen-regulated genes. Quantitative PCR analysis typically 
requires consistently expressed reference gene(s) as an internal control for 
differences in the amount of starting material (cDNA) between the samples. An 
optimal reference gene should have 1) a low variability across different biological 
samples (e.g., between different individuals and subtypes of normal tissue), 2) a 
level of expression that is not too far from the expression level of the regulated gene 
of interest and 3) consistency between the different treatments. Normalization can 
involve either just one or several reference genes. In paper II, the two reference 
genes that were selected were ?-actin (bactin), which was a frequently used 
housekeeping gene at the time, and ubiquitin (uba), which was selected based upon 
literature data and our own microarray results. Bactin had a clear tendency to be 
regulated in the fish that were exposed to the high EE2 concentration, while uba 
fulfilled the abovementioned criteria. Accordingly, only uba was used as a 
reference gene. It was later shown that the expression of hepatic bactin is regulated 
in fish that are exposed to estrogens (Filby and Tyler, 2007). In paper III, 
hypoxantine phosphoribosyltransferase (hprt) and a tata box binding protein (tbp) 
were evaluated in addition to ubiquitin, as they were suggested to be appropriate 
housekeeping genes for expression profiling of estrogens in the fathead minnow 
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(Filby and Tyler, 2007). The assay for tbp could not be optimized due to too low 
amplification efficiency. Hprt was clearly regulated between several of the 
treatment groups, while the expression of uba was consistent. Consequently, only 
uba was used as a reference gene. In paper IV, again two reference genes were 
evaluated, uba and tubulin alpha (tuba), which were selected based upon our 
microarray results and literature data. Both fulfilled the criteria for good reference 
genes.  
3.6. Enzymatic assays 
In paper IV, the analysis of enzymatic activities and glutathione levels was 
performed in order to validate hypothesis that were created from the microarray 
results. The activities of the hepatic antioxidant enzymes glutathione S-transferase, 
glutathione reductase and catalase, the activity of cytochrome P450 1A (Cyp1a) and 
the levels of glutathione were assessed through the use of well-established methods 
that had been previously applied in rainbow trout. All measured enzyme activities 
and glutathione levels were measured spectrophotometrically, with the samples 
diluted in a physiological buffer and the addition of a substrate or electron donor. 
The accumulation of product or the consumption of reagents was then monitored 
spectrophotometrically over time (Carney Almroth, 2008).  
The regulation of antioxidant enzyme activity is complex, and hepatic 
antioxidant enzymes are often less responsive than, for example, Cyp1a (van der 
Oost et al., 2003). The low responsiveness can be partly explained by the rather 
high activities of glutathione S-transferase and catalase in contrast to the low Cyp1a 
activity in the liver under normal conditions. Measurements of antioxidant enzyme 
activities are, therefore, usually combined with the analysis of oxidative damage 
products, such as protein carbonyls, lipid peroxidation products or oxidative DNA 
damage (Carney Almroth, 2008). Analysis of protein carbonyls and lipid 
peroxidation products in the exposed fish in paper IV were considered, but we 
decided no to proceed with this since there was no tendency towards altered 
glutathione levels or antioxidant enzyme activities. 
In the places I go there are things that I see 
That I never could spell if I stopped with the Z. 
I'm telling you this 'cause you're one of my friends. 
My alphabet starts where your alphabet ends! 
Dr Seuss 
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Figure 7. a) Median sequence similarity and the number of predicted orthologs in 16 non-target 
species compared to the human drug targets. The boxes indicate 25% and 75% quantiles. b) GO 
categories for the drug targets in human and in 16 non-target species. Some drug targets were 
annotated to more than one functional category. Note that the ortholog prediction in X. laevis is 
based on comprehensive EST data and not on a fully sequenced genome. The figures are 
reproduced with permission from (Gunnarsson et al., 2008) copyright 2009 American Chemical 
Society. 
 
Receptors constitute an important group of pharmacological targets, with as 
many as 40% of all FDA approved drugs elicit their effects through receptors 
(Overington et al., 2006). Thus, the choice of environmental test species is 
particularly important for drugs that target receptors. Most drugs from this group 
are therefore predicted to have a low potency in non-vertebrates. Enzyme drug 
targets, on the other hand, were more ubiquitously present. Generally speaking, the 
drugs that target enzymes could be expected to affect a wider range of species, 
including invertebrates. 
The presence of a drug target ortholog in a non-target species does not guarantee 
that a functional interaction with the drug can occur. However, we also presented 
data from the literature that supports the idea that an ortholog prediction can often 
indicate the ability of a conserved drug target protein to interact with the human 
drug. For example, the predicted well-conserved enzyme aldehyde dehydrogenase 
is inhibited by the drug disulfiram (which in humans is used as a alcohol deterrent), 
in humans as well as in a bacterium and a plant (Velasco-Garcia et al., 2006). 
Similarly, the 5HT transporter (sodium dependent serotonin transporter) is inhibited 
by SSRI drugs in humans, zebrafish (Wang et al., 2006), D. melanogaster 
(Demchyshyn et al., 1994) and a flatworm (Patocka and Ribeiro, 2007). The plant, 
the alga and the fungi were predicted to not have any orthologs to the 5HT 
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accordingly, a very high concentration of fluoxetine (1 mg/L) had no effect on 
either wet weight, frond number, chlorophyll or cartenoids in the plant Lemna gibba 
(Brain et al., 2004).  
Based on our results, we propose that aquatic environmental risk assessment for 
drugs with human targets should include comprehensive studies on aquatic 
vertebrates. These results also suggests that toxicity data that are generated from a 
species that is missing a drug target ortholog might not be able to predict the 
toxicity of that same drug in another species that has the drug target ortholog. The 
copepode, Nitocra spinipes, does not have an ortholog to the estrogen receptor. 
Consequently, the NOEC value of 0.05 mg/L for chronic toxicity of EE2 in the 
copepode (Breitholtz and Bengtsson, 2001) is not protective for fish, even if an 
assessment factor of 1000 was applied.  
In Sweden, data from the environmental risk assessments that are required for 
the approval of new drugs in the EU and USA (se also section 1.3) are made easily 
available to prescribers and users at the web page www.fass.se. Although this is a 
good initiative, most of the available data are based upon results from acute tests, 
and data regarding effects on fish are often lacking. It is therefore important to 
recognize the limitations of this dataset for a complete environmental risk 
assessment perspective. The full list of all orthology predictions that were presented 
in paper I is available as supplementary material (Gunnarsson et al., 2008). The 
orthology data, however, should be interpreted carefully on an individual basis. The 
prediction of orthologs can be very difficult, especially when many paralogs are 
present and, even if the orthology prediction is correct, it does not guarantee ligand 
binding or conserved function. A more precise prediction of a potential drug target 
interaction might be possible with better knowledge about drug-binding domains. 
Sakharkar et al. (2007) have summarized protein family domains (Pfam) that are 
related to drug binding and called them druggable domains . Unfortunately, many 
of these domains are too general to provide additional useful information to predict 
the ability of a protein to interact with a drug in an evolutionarily distant species. 
The database Supersite (http://bioinformatics.charite. de/supersite) was recently 
released. It contains three-dimensional protein structures and ligand-binding site 
information for 1,300 drugs, as well as some evolutionary information (Bauer et al., 
2009). Such information on drug binding domains could improve the current 
predictions.  
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4.1.2. Future perspectives - extending the orthology prediction 
Accurate predictions of evolutionary conservation of all proteins, as well as their 
downstream pathways, that are known to interact with drugs may increase our 
understanding of both pharmacokinetics and pharmacodynamics in non-target 
species. For example, predictions of evolutionary conserved transporter proteins 
may enhance our understanding of the uptake and distribution of drugs. Passive 
diffusion through the lipid bilayer of the cell is often considered the dominant 
process by which a drug is taken up by the cell (Lipinski et al., 2001). However, 
Dobsen and Kell (2008) argue that carrier-mediated and active uptake of 
pharmaceuticals may be more common than traditionally assumed. Indeed, the 
evidence is growing for transporter-mediated drug uptake in those specific cases 
where it has been studied. Carrier-mediated and active drug uptake, for example, 
can lead to drugs concentrating in specific tissues. The presence of a conserved 
transporter protein might also explain why certain drugs bioaccumulate in some 
aquatic organisms to a higher degree than predicted from the drugs’ lipophilicity 
(e.g., LogP). Data on the uptake and distribution of pharmaceuticals, as well as the 
molecular characterization of transporters in wildlife species, are needed to validate 
the importance of conserved transporter proteins.  
Another possible extension of the ortholog prediction approach could be to 
predict evolutionary conservation of pathways downstream from the drug targets. 
Such information may provide input for an increased understanding of drugs’ mode 
of action and means for the identification of affected physiological endpoints in 
wildlife species. The conserved counterparts of human pathways have been 
predicted in 22 species by the Reactome Project (www.reactome.org). Most of the 
species are mammalian model species or human pathogens, but the representatives 
for a few, perhaps more ecotoxicologically relevant, taxonomic groups are also 
included, such as the spotted green pufferfish (Tetraodon nigroviridis). The 
pathways that are affected by pharmaceuticals have not been as extensively studied 
as drug targets in mammals, and information about pathways in non-traditional 
model species is still very sparse. In general, a better understanding of the 
physiology of the wildlife species that are exposed to pharmaceuticals is needed. 
Nevertheless, we believe that large-scale comparisons of conserved proteins and 
pathways can still aid in the prioritization of which drugs need further attention for 
assessment of their environmental risks and which organisms should be prioritized 
for testing and what endpoints are appropriate. 
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4.2. Gene expression changes induced by estrogens
4.2.1. Microarray analysis of fish exposed to EE2 (paper II) 
This paper aimed to identify sensitive and robust hepatic gene expression 
changes that could potentially be used as additional biomarkers for exposure to 
estrogens in fish, which is an organism group that has functionally conserved 
estrogen receptors. Gene expression profiles were characterized in juvenile rainbow 
trout that were exposed to a measured concentration of 0.87 and 10 ng EE2/L using 
the salmonid cDNA microarray from GRASP. The higher concentration was used 
to guide the identification of the more subtle responses that were induced by the 
low concentration. Twenty-nine potentially sensitive gene responses, all of which 
responded in a dose dependent manner, were identified. Transcripts encoding zona 
pellucida (zp) proteins were among these sensitive estrogen responsive genes, while 
vtg was not up-regulated by the low concentration of EE2. Induction of the zp genes 
has been previously suggested to be more sensitive than vtg (Celius et al., 2000; 
Thomas-Jones et al., 2003). 
Ensemble 
Transcript Annotation 
O. mykiss,
juvenile, 
EE2, 10 ng/L
(Gunnarsson et 
al., 2007) 
O. mykiss,
male, EE2
50 ng/L 
(Hook et al., 
2006) 
O. mykiss,
juvenile, E2
Dietary 5ppm  
(Tilton et al., 2006) 
O. latipes,
male, E2
100 ng/L 
(Kishi et al., 
2006) 
61165 Vitellogenin ?     
61744/ 61751/ 
65820 
Zona pellucida 
protein 3 ?     
49240 Transducer of ERBB2, 1a ?     
56088/ 77745/ 
8439/ 24598 
Zona pellucida 
protein 2 ?     
26180/ 33724 Fatty acid binding protein 3  or 7  ?     
55579/ 74814 Peptidylprolyl isomerase B ?     
59139/ 64339 Non-metastatic cells 2 (Nme2) ?     
56095 Fatty acid binding protein 10 ?     
2842 Cytochrome P450 ?     
Figure 9.  Transcripts or groups of transcripts affected by estrogen treatment (17-?-ethinylestradiol, 
EE2 or 17?-estradiol, E2) in at least three out of four microarray studies. Dark grey refers to an 
estrogen-induced mRNA expression, light grey refers to suppression whereas white refers to either 
missing value or not significantly regulated. Note that different microarray platforms and statistical 
methods were used in each study.  
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A meta-analysis was also performed in order to identify robust estrogen-
responsive genes (Figure 9). The microarray results from the present study and 
three similar studies using different fish species, estrogens and microarray platforms 
were compared using the zebrafish genome as a reference. Transcripts that 
presumably corresponded to nine genes or groups of paralogous genes were 
differentially regulated by estrogens in at least three of the four studies. Two of 
these genes, which were confirmed by qPCR, fulfilled the criteria of high sensitivity 
and robustness. One was the previously known sensitive estrogen responsive gene, 
zp3, and the other was a novel estrogen responsive gene in fish, non-metastatic cells 
2 (nm23, nme2). 
4.2.1.1. Nme2 
Nme2 is a multifunctional protein that belongs to a larger class of nucleoside 
diphosphate kinases. The protein is highly conserved throughout evolution, and the 
salmon Nme2 shows high similarity to the human NME1 (NM23-H1) and NME2 
(NM23-H2) proteins. A phylogenetic analysis suggests that the NME1 and NME2 
are in-paralogs with respect to the teleost fish genomes (i.e., they have arisen by 
gene duplication after the speciation event that separated modern teleost fish from 
the human lineage) (Murphy et al., 2000). It is assumed, therefore, that the rainbow 
trout genome only has one ortholog of the NME1 and NME2 proteins. In humans, 
the NME2 encodes the c-MYC transcription factor (Postel et al., 1993). NME1 has 
DNAse and histidine protein kinase activities and is also known to limit metastasis 
(Curtis et al., 2007). Furthermore, NME1 gene expression is induced by estrogens 
(Lin et al., 2002), and NME1 also interacts with the estrogen receptor 1 (estrogen 
receptor ?, ESR1) and can influence ESR1-mediated gene expression (Curtis et al., 
2007). It is suggested that the metastasis-suppressive effects of NME1 is mediated, 
at least in part, by its capacity to limit expression of cathepsin D (CTSD) and the 
proto-oncogene BCL2. Both these genes are estrogen-inducible, and their proteins 
are involved in cell migration, apoptosis and angiogenesis (Rochefort et al., 1990; 
Biroccio et al., 2000).  
The meta-analysis revealed that nme2 was induced in all three microarray 
studies with rainbow trout. The study with Japanese medaka (Oryzias latipes) did 
not report nme2 as an estrogen-responsive gene, but it is unclear if nme2 was 
represented on the microarray (Kishi et al., 2006). Recently, Tobias Österlund in 
our lab performed an extended meta-analysis with five microarray studies on fish 
that were exposed to estrogens (Österlund, 2009). He identified nme2 as slightly up-
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regulated in estradiol-treated stickleback (Geoghegan et al., 2008), which supports 
the hypothesis that estrogen also regulates nme2 in fish. The physiological function 
of Nme2 in fish, however, remains to be determined. 
4.2.2. Induction of estrogen-responsive genes by different STP 
effluents (paper III)  
In paper III, we investigated the gene expression of nme2, zp3 and vtg, along 
with four other estrogen-responsive genes, with the aim to compare six different 
sewage treatment technologies’ ability to reduce estrogen-induced gene expression 
changes in exposed male fish. STP effluents often contain a mixture of estrogenic 
compounds such as EE2, natural hormones and industrial phenols. The total 
combined activity of the estrogenic substances may be sufficiently high to cause 
feminization of fish in the environment (Purdom et al., 1994; Sumpter and Jobling, 
1995; Larsson et al., 1999; Jobling et al., 2002a). Improvements to and/or the 
implementation of new sewage treatment technologies have been suggested to 
remove micro-contaminants, such as pharmaceuticals and estrogenic substances 
(Clara et al., 2005; Esplugas et al., 2007; Koh et al., 2008; Laven et al., 2009).  
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Figure 10. Principal outline of the different sewage treatment lines and the reference fish. Fish were 
exposed to tap water or effluent from the conventional line (C), C with a sand-filter (Cs), Cs with a 
moving bed biofilm reactor (MBBR), Cs with ozonation (O3), Cs with both O3 and MBBR (O3 + 
MBBR) or the membrane bioreactor line (MBR). 
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In this study, one municipal sewage influent was treated with six different treatment 
technologies in parallel (Figure 10), and fish were exposed to the different effluents. 
The gene expression of zp3, esr1, nme2, cyp1a, estrogen receptor 2a and 2b (esr2a 
and esr2b) were then analyzed in the exposed fish. 
The STP lines with the advanced treatment technologies ozonation and/or 
moving bed biofilm reactor (MBBR) removed the majority of the measured 
estrogenic chemicals from the effluents. For example, EE2 and E2 were removed to 
a level below detection limits. However, the biological data suggested that the 
effluent from the MBBR line still induced some estrogenic responses in the exposed 
male fish. Ozonation was required to remove all measured biological effects.  
 Advanced treatment technologies, such as ozonation, can be very effective in 
removing pharmaceuticals and estrogenic substances (Esplugas et al., 2007; Laven 
et al., 2009), however, they are generally expensive to implement (Koh et al., 
2008). The chemical oxidation, which is produced by ozonation, can also 
potentially create hazardous by-products (Petala et al., 2008), and this risk needs to 
be further studied. 
In this study, the fish were exposed to 100% effluent, while a substantial 
dilution commonly occurs when STP effluents reach surface waters. It may not be 
necessary to remove so much of the estrogenic substances if an effluent is heavily 
diluted when it reaches surface waters, especially if the substances of concern are 
degradable in nature. The addition of a sand-filter to the conventional line (Cs), 
which is a solution that is quite common in Swedish STPs, reduced the gene 
expression of vtg, esr1 and zp3 the most dramatically (Table 1). If only the removal 
of estrogenic substances is considered, the addition of a sand-filtering step might be 
a suitable and relatively inexpensive improvement for many STPs.  
The membrane bioreactor (MBR) technology reduced the expression of 
estrogen-responsive genes to baseline levels (Table 1). However, the fish exposed 
to this effluent or the Cs effluent had enlarged livers, which could be caused by a 
variety of chemicals. The cause behind the enlarged livers could be important to 
investigate further. The fish exposed to the Cs effluent had a slightly induced 
expression of cyp1a in addition to enlarged livers. Induction of cyp1a gene 
expression is a biomarker for contaminant exposure. Many chemicals, such as 
polychlorinated biphenyls (PCBs), polycyclic aromatic hydrocarbons (PAHs), some 
pesticides and pharmaceuticals, can induce cyp1a  (Whyte et al., 2000).  
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Cost is an important aspect to consider when an implementation of a new 
sewage treatment technology is discussed, but the costs need to be weighed against 
the possible benefits. Decreasing the risk of effects on effluent-exposed wildlife 
species is clearly one benefit that should be evaluated for any candidate treatment 
technology. Unfortunately, determining what biological effect that may pose a risk 
to cause detrimental effects in the environment and what price we are willing to pay 
to avoid this is difficult. 
4.2.3. Biomarkers of estrogen exposure (papers II, III and IV)  
We have analyzed several estrogen responsive genes with the argument that a 
combination of responses increases the evidence that the fish have indeed been 
exposed to estrogenic substances to such a degree as to affect estrogen-regulated 
physiological processes (Table 1). We have also been able to evaluate the 
usefulness of nme2 as a biomarker. Vtg, zp3, nme2 and esr1 are all genes that are 
induced by estrogens and have estrogen-responsive elements (EREs) in their 
promoters (Lin et al., 2002; Arukwe and Goksoyr, 2003; Yu et al., 2006). The 
ligand-activated estrogen receptor regulates transcription by binding to the EREs, 
interacting with other transcription factors and interacting with co–regulators, such 
as activators or repressors. Nme2 did not have the same pattern of regulation as the 
other genes when the gene expression results from papers II, III and IV were 
compared (Table 1). The estrogenic chemicals present in, for example, the effluent 
from the conventional line did not significantly induce gene expression of nme2 in 
exposed fish. Many factors may regulate the expression of nme2, and the estrogen-
induced gene expression of nme2 does not seem to follow a traditional dose-
response pattern. Thus, the regulation of nme2 is probably not specific or robust 
enough to work as a biomarker for estrogen exposure in a complex exposure 
situation. However, nme2 could still have some value in the assessment of single 
estrogenic chemicals, if used together with other biomarkers of exposure, such as 
zp3 and vtg. 
Zp3 and esr1 showed a similar pattern of induction in all studies, while vtg was 
not induced by the low concentration of EE2 in paper II or by exposure to the 
effluent in paper IV. The zona pellucida genes are also referred to as vitelline 
envelope proteins or zona radiata proteins in fish (Larsson et al., 1994). Similar to 
Vtg, they are, in many fish species, produced in the liver under the influence of 
estrogen in maturing females and transported to the growing oocytes. There, they 
are deposited to form the extracellular coat that surrounds the oocyte of all 
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vertebrates. In mammals, as well as in some fish species, however, the zona 
pellucida proteins are synthesized within the ovary rather than the liver. Zona 
pellucida genes are not expressed in the liver of zebrafish, for example, and their 
expression in the ovaries is not under the regulation of estrogen (Liu et al., 2006). 
Thus, in fish that lack hepatic Zp synthesis, the induction of zp genes in the liver 
will not be useful as biomarkers of exogenous estrogen exposure. In salmonids, 
which are a group of fish that have hepatic Zp synthesis, the induction of zp genes 
in the liver is known to be more sensitive to estrogen exposure than vtg (Celius et 
al., 2000; Thomas-Jones et al., 2003; Gunnarsson et al., 2007) , but the specificity 
of the Zp induction for estrogens has been questioned (Larsson et al., 2002; 
Rotchell and Ostrander, 2003; Berg et al., 2004).  
Table 1. Summary of the fold change of the different estrogen-regulated genes vitellogenin (vtg), 
zona pellucida protein 3 (zp3), estrogen receptor 1 (esr1) and non-metastatic cells 2 (nme2). 
Treatment (ng/L)
vtg
fold change
zp3
fold change
esr1
fold change
nme2
fold change 
EE2 (10)a 540(p=0.001) 
84
(p=0.002) NA 
1.5
(p=0.01) 
Pa
pe
r I
I 
EE2 (0.87)b 1.0 (p=0.9) 
3.5
(p=8 × 10-4) NA 
1.4
(p=0.01) 
 
C (6.3 E1, 0.3 E2, 0.2 
EE2)c
1500
(p= 6 × 10-12)
5.1
(p=3 × 10-6)
2.3
(p=6 × 10-7)
1.2 
(p=0.2) 
Cs (0.7 E1, 0.2 E2, 
0.2 EE2)d
23
(p=1 × 10-4)
2.1
(p=0.04) 
1.8
(p=5 × 10-4)
1.5
(p=0.02) 
MBR (0.5 E1, <0.1 
E2, 0.1 EE2)e
1.8 
(p=0.3) 
1.6 
(p=0.1) 
0.29 
(p=0.6) 
1.5
(p=0.03) P
ap
er
 II
I 
O3 (0.2 E1, <0.1 E2, 
<0.1 EE2)f
2.3 
(p=0.3) 
1.4 
(p=0.7) 
0.7 
(p=0.2) 
1.2 
(p=0.1) 
 
Pa
pe
r
IV
 
PETL effluent  
(0.6 E3)g
1.4 
(p=0.2) 
1.9
(p=0.005) 
1.7
(p=0.006) 
1.2
(p=0.009) 
To allow comparisons between studies, all of the p-values were re-calculated with a two sided t-test, 
and no correction for multiple testing was applied. Bold indicates a significant regulation (p value < 
0.05). NA = data not available. The fold changes were calculated as the ratio between gene 
expression in the exposed fish and the expression in the reference fish. The gene expression levels 
in the reference fish in paper III were excluded from the statistical analysis in the original study, 
since 30 out of the 44 fish were killed by an unannounced raise in the Cl2-concentration in the 
drinking water early during the exposure. Based on similar expression levels in the reference fish 
and the fish that were exposed to effluent with low levels of estrogens and on follow-up experiments 
in 2009 (unpublished data), we believe that the data from the reference fish nevertheless provides 
some information on the basal expression levels. The gene expression in those reference fish was 
thus used to enable comparisons between the different studies that are presented in the table. The 
different treatment lines in paper III were: conventional line (C), conventional line with a sand filter 
(Cs), the line with a membrane bioreactor (MBR) and the Cs line with ozonation (O3) (see Figure 
10). The measured estrogens and their potencies: 17-?-ethinylestradiol (EE2), >17?-estradiol (E2), 
>estrone (E1) and >estriol (E3). The number of biological replicates in each study was: a) (n=4, 
n=4),b) (n=8, n=8),c) (n=8, n=6),d) (n=6, n=6), e) (n=6, n=6),f) (n=6, n=6) and g) (n=9, n=10).  
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In paper IV, it is unclear what chemicals induced zp3 and esr1. The 
concentrations of EE2, estrone (E1), estradiol (E2) and estriol (E3) were analyzed in 
the effluent, but only E3 was detected. Given the high dilution of the effluent 
(1:500), the calculated exposure concentration of E3 was not sufficient to explain 
the observed induction. The potential presence of estrogenic industrial phenols, 
such as nonylphenol or other estrogenic chemicals that were not measured could 
explain the weak estrogenic effect. 
Estrogens can induce vtg several thousand-fold, and it has been shown in other 
studies that the induction corresponds fairly well to the magnitude of the exposure. 
In our studies, however, the gene expression of zp3 agrees better with the measured 
concentrations of estrogen-acting substances in papers II and III. The three-fold 
difference between the vtg induction at the high concentration of EE2 in paper II 
and the induction of vtg by the conventional effluent in paper III, however, is 
marginal considering that a vtg induction could span several orders of magnitude, 
and could potentially be explained by technical variability in the qPCR 
measurements or by biological variability between the reference fish in the two 
studies. 
4.2.3.1. The connection to adverse effect  
The utility of vtg and, consequently, also zp3 in male fish as biomarkers of 
potentially adverse effects is somewhat controversial. I agree with Hutchinson et al. 
(2006) that biomarkers for endocrine disruption should be viewed as signposts and 
not traffic lights. An induction of vtg or zp3 in the field situation does not 
necessarily imply an adverse effect for the individual or the population. However, 
in a controlled lab experiment, an induction of vtg and/or zp3 can serve as a 
biomarker of potential adverse effects. In other words, reproductive effects may 
occur if the fish were to be continuously exposed to the same concentration of the 
investigated estrogen for a prolonged time period or briefly exposed during a 
particularly sensitive time window. Such time windows exist during the very 
sensitive sexual differentiation period of the brain and gonads, such as very early 
during development or during the reproductively active phase when a negative 
feedback of estrogen on the hypothalamic-pituitary axis may interfere with the 
hormonal signaling that is required for producing viable gametes. 
Manufacturers of pharmaceuticals have also showed an interest in illuminating 
how to use or possibly not use molecular biomarkers for estrogenic effects. For 
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example, Caldwell et al. (2008) conclude in their paper that the induction of Vtg in 
male fish should be considered as a biomarker of exposure and not of effect. They 
evaluated all papers investigating EE2 and reproductive effects that were published 
before mid-2007 with the aim to derive an aquatic predicted no-effect 
concentration. Twelve of the studies that passed their selection criteria reported 
both a reproductive NOEC and Vtg NOEC in fish. Two studies showed that Vtg 
induction was less sensitive than reproductive endpoints were (Länge et al., 2001; 
Parrott and Blunt, 2005), three studies showed the opposite pattern and seven 
studies reported the same NOEC concentration for the Vtg induction and 
reproductive endpoints (Caldwell et al., 2008). My conclusion from the presented 
data is that Vtg induction appears to be a rather good biomarker of potentially 
adverse effects. In addition, several of the included studies report reproductive 
effects at concentrations around 1 ng/L. Thus, specific gene expression changes that 
are induced by estrogens at this concentration could serve as signposts/biomarkers 
for potentially adverse effects caused by estrogens. 
Caldwell et al. (2009) further suggested 0.35 ng/L as the aquatic PNEC for EE2, 
based up on an analysis of 39 papers that covered 26 species. More than half of the 
included species are not believed to have a functionally conserved estrogen 
receptor, which means that those species will naturally have much higher NOEC 
values than species that have a functional estrogen receptor (see also section 4.1.1.). 
Consequently, the derived aquatic PNEC value will depend on how many of the 
species included in the analysis are missing estrogen receptor orthologs. 
Nevertheless, the suggested PNEC value of 0.35 ng/L is below most reported 
LOEC values in fish and is, therefore, likely to be protective for the majority of fish 
species if no other estrogens are present, which could add to the total effect.  
4.3. Microarrays and exposure to complex mixtures  
Microarray analysis could be useful for the development of biomarkers of 
exposure (paper II) as well as to increase the knowledge about the toxicological 
mode of action. The mechanism of sub-lethal toxicity of a complex mixture, such as 
an effluent, could also be explored with microarray analysis.  
4.3.1. Effluent from bulk drug manufacturers (paper IV) 
Larsson et al. (2007) and Carlsson et al. (2009) recently showed that an effluent 
from bulk drug manufacturers contained a mixture of a wide range of APIs in high 
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concentrations along with a variety of other chemicals (see also section 1.1.). The 
investigated effluent came from a treatment plant, PETL, that regularly receives 
process water from about 90 pharmaceutical industries in Patancheru, India. Many 
of the APIs that were detected in the effluent in concentrations higher than 100 
μg/L were antibiotics. This raises concerns about the development of antibiotic 
resistance, and our research group has several ongoing studies that address that 
matter. 
Carlsson et al. (2009) investigated the potency of the effluent from PETL to 
aquatic vertebrates. As little as 0.2% of the effluent was sufficient to strongly 
reduce the growth of tadpoles (Carlsson et al., 2009). However, the underlying 
toxicological mode(s) of action and which substances in the mixture are the most 
biologically potent were not known. The aim of paper IV was to start to unravel the 
mechanism behind this toxicity to aquatic vertebrates. Therefore, we exposed fish to 
0.2% of the effluent and analyzed the effects on hepatic global gene expression 
along with other physiological endpoints.  
Cyp1a was the most significantly regulated gene, and the exposed fish also 
showed a four-fold increase in Cyp1a activity. The detoxification enzyme Cyp1a is 
involved in the metabolism of many different organic chemicals, such as 
polychlorinated biphenyls (PCBs), polycyclic aromatic hydrocarbons (PAHs) 
(Whyte et al., 2000) and pharmaceuticals (Lee et al., 2006).  Many of the chemicals 
that are substrates for Cyp1a metabolism are agonists to the ligand-activated 
transcription factor, aryl hydrocarbon receptor (AhR), which can induce the 
expression of genes with xenobiotic responsive elements (Köhle and Bock, 2007). 
Cyp1a can be induced via the Ah-receptor or via other mechanisms (Hu et al., 
2007). A few genes that are known to be regulated via the Ah-receptor were 
affected, while other AhR responsive genes had no altered gene expression in the 
exposed fish. The observed ethoxyresorufin-O-deethylase (EROD) induction may 
be an indication of adverse effects that are mediated via AhR, but a longer exposure 
time or exposure to a higher concentration is needed to elucidate if such a 
mechanism contributes to the toxicity of the effluent.  
The concentration of more than 200 different chemicals, such as APIs, organic 
solvents, metals and pesticides, have been analyzed in the effluent  (Larsson et al., 
2007; Carlsson et al., 2009) and, to our knowledge, no individual chemical was 
detected at levels that could explain the observed EROD induction in the exposed 
fish. This does not exclude, however, the possibility that an individual API or non-
pharmaceutical chemical was responsible, as many of these have not been tested in 
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fish. Several fluoroquinolones were measured in very high concentrations, but they 
are known to inhibit rather than induce hepatic CYP1A activity in mammals 
(McLellan et al., 1996; Regmi et al., 2005). Inhibition of Cyp1a enzyme activity 
could lead to an inefficient metabolism of its substrates, which would imply that 
low concentrations of Cyp1a substrates, which are often inducers, could be 
sufficient to up-regulate cyp1a transcription, if any inhibitors are present in the 
mixture. Data from a pilot study (data not shown) showed that the PETL effluent 
first starts to inhibit EROD activity in ?-naphthoflavone (BNF)-stimulated cells at a 
dilution with roughly 2% effluent. The inhibitory effect of the fluoroquinolones in 
fish that are exposed to 0.2% effluent, therefore, is assumed to be low.  
Several oxidative stress-related genes, such as glutathione S-transferase ? 
(gstp), glutathione peroxidase (gpx) and superoxide dismutase (sod1, SOD 
[Cu/Zn]), were slightly up-regulated in the exposed fish. In order to test if the 
exposed fish were suffering from oxidative damage, the hepatic levels of 
glutathione and the enzyme activities of glutathione S-transferase, glutathione 
reductase and catalase were measured. The exposed fish had no altered levels of 
glutathione or antioxidant enzyme activities, which suggested that they were not 
suffering from oxidative damage. Oxidative damage cannot be excluded at a higher 
concentration or a longer exposure time.   
The blood chemistry analysis showed that the exposed fish had significantly 
increased plasma phosphate and cholesterol levels when compared to the control 
fish. Elevated phosphate blood levels are associated with renal failure and 
hypoparathyroidism in mammals (Berner and Shike, 1988). High concentrations of 
the fluoroquinolone, ciprofloxacin, have been associated with oxidative stress in the 
liver and kidney in mammals (Gurbay and Hincal, 2004; Weyers et al., 2008) but it 
is unknown how ciprofloxacin affects fish. The increase in cholesterol levels has 
some support in the pattern of regulated genes. Regulated transcripts with, GO-
terms such as cellular metabolic process (GO:0044237) and triacylglycerol 
metabolic process (GO:0006641), were overrepresented in the list of the top 300 
most significantly regulated transcripts. Transcripts with the GO-term cholesterol 
catabolic process (GO:0006707) were overrepresented in the top 600 list, according 
to an analysis that was performed with the GOrilla web service (Eden et al., 2009) 
(http://cbl-gorilla.cs.technion.ac.il/). Further studies are needed to evaluate the 
physiological importance of the increased levels of plasma phosphate and 
cholesterol in the exposed fish. 
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In conclusion, the results from this study show that exposure of fish to a high 
dilution (1:500) of the PETL effluent affects the expression of hepatic genes that are 
involved in the biotransformation and detoxification of chemicals and 
pharmaceuticals. We were not able to link the pattern of regulated genes to any 
specific group of chemicals or pharmaceuticals, but the observed alterations could 
serve as basis for hypothesizing which pharmaceuticals or compounds in the 
effluent that are the most biologically potent to aquatic vertebrates. 
The combined conclusion from this and previous studies (Larsson et al., 2007; 
Carlsson et al., 2009) is that the wastewater treatment at PETL is insufficient, which 
implies that one of the world’s largest centers for bulk drug production pollutes 
surface water to an extent that strongly affect aquatic life. PETL serves bulk drug 
manufacturer that exports their APIs to the world market. Many pharmaceutical 
products, including products on the Swedish market, contains APIs from this area 
(Larsson and Fick, 2009). Thus, Western countries, such as Sweden, have a 
responsibility to deal with the environmental problems that are related to the 
production of APIs in this area. However, information regarding the origin and the 
production conditions of the APIs in different pharmaceutical products is not easily 
available, which prevents prescribers and consumers from making informed 
decisions. An increased transparency would enable consumers and large purchasers, 
such as county councils, to put pressure on the pharmaceutical industry sector to 
reduce the environmental impacts throughout the production chain.  
4.4. Microarrays and environmental risk assessments of 
pharmaceuticals
The potential of microarray analysis to aid in environmental risk assessment has 
been described in numerous articles (see also section 1.5.1) (Snape et al., 2004; 
Ankley et al., 2006; Ju et al., 2006; Lettieri, 2006; Steinberg et al., 2008). Ankley et 
al. (2006) described a conceptual timeline for the development and integration of 
toxicogenomic data into ecotoxicological regulatory programs. They suggest that 
we have just entered the phase of validation and “phenotypic anchoring” of the 
results from microarray studies.  
A large proportion of the published ecotoxicologically relevant microarray data 
explore the effects of pharmaceuticals. Pharmaceuticals make up a group of 
chemicals for which a “proof of concept” is feasible since much is known about the 
molecular and toxicological responses to drugs in mammals (see section 1.4). In 
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addition, extensive sets of mammalian microarray data that describe responses to 
individual drugs are available (Fostel, 2008; Natsoulis et al., 2008).  
Microarray analysis of drug-exposed, environmentally relevant species has been 
used to increase our understanding of toxicological modes of action. Heckmann et 
al. (2008) suggested a molecular mode of action of ibuprofen in D. magna that was 
based upon microarray data, and he linked the molecular responses to specific 
adverse effects. The analysis was, however, conducted with very high 
concentrations of ibuprofen, which only included levels that were more than 1000 
times higher than those detected in the environment. Another example involved the 
analysis of the effects of the neuropharmaceutical mianserin in zebrafish (van der 
Ven et al., 2006), again using considerably higher concentrations than those 
normally found in the environment. Other studies have shown that different classes 
of chemicals induce different patterns of expression (Poynton et al., 2007; Williams 
et al., 2008). However, to my knowledge, there is no study that describes how a 
certain gene expression pattern has been used to pinpoint the effects of a chemical 
or group of chemicals within an unknown mixture. Falciani et al. (2008) started to 
approach this aim in a recent paper on the microarray analysis of European flounder 
(Platichthys flesus) that were sampled from field sites that were either clean or 
polluted in different ways. The paper described how a computational approach, 
which included data from previous field samplings and controlled lab-exposure 
experiments using single compounds (Williams et al., 2008), could identify gene 
expression patterns that predict which one of three sites the flounder was sampled 
from (Falciani et al., 2008).  
There are very few published papers that use microarrays to characterize the 
mechanism of toxicity of complex mixtures, such as effluents (Steinberg et al., 
2008). The microarray data in the study of Moens et al. (2007) with regard to an 
industrial effluent provided clues about the toxicological mode of action, although 
the chemicals that actually resulted in the toxicity remained unknown (Moens et al., 
2007). Identifying causative agents and unraveling the molecular mode of action 
that underlies various toxic effects that result from the exposure to a complex 
mixture is a highly challenging task.  
The use of microarray analysis on environmentally relevant species has just 
begun to emerge, and many issues remain to be solved. More studies that connect a 
specific gene expression pattern to a certain adverse effect and/or a certain class of 
chemicals are the first steps towards the development of predictive gene expression 
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patterns. Requirements for such studies include a vast understanding of the time and 
dose dependency of the gene response and a correlation to particular phenotypes.   
The development of databases and tools for predictive toxicogenomics is part of 
the ongoing research within the pharmaceutical industry (Maggioli et al., 2006; 
Fostel, 2008; Natsoulis et al., 2008). In drug development, predictive 
toxicogenomics holds promise to aid in the preclinical evaluation of drug candidates 
by predicting toxic effects and identifying the mechanisms of toxicity. Information 
from such efforts may be useful for cross-species extrapolation and environmental 
risk assessment. However, the development of bioinformatical and statistical 
methods is needed for reliable interpretations of the microarray data and cross-
species comparisons. Equally important is an increased understanding of the 
molecular responses and the general physiology of ecotoxicologically relevant 
species. 
Don't give up! I believe in you all. 
A person's a person, no matter how small! 
Dr. Seuss
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5. SUMMARY AND CONCLUSIONS
To summarize, different genomic approaches have been used to increase the 
understanding of the effects of pharmaceutical residues in the environment. The 
conclusions from the papers, upon which this thesis is based, are summarized 
below: 
 
- Comparative pharmacology (paper I)  
We show that the majority of the specific targets for drugs are evolutionarily 
conserved in aquatic vertebrates, while invertebrates and plants lack orthologs to 
many of the drug targets for human pharmaceuticals. Therefore, we propose that 
aquatic environmental risk assessments for human pharmaceutical drugs should 
include comprehensive studies on aquatic vertebrates. The presented predictions 
can also serve as a basis for the interpretation of the relevance of existing 
ecotoxicity data and the identification of potentially sensitive wildlife species 
that could be used in the environmental risk assessment of pharmaceuticals.  
- Microarray analysis of fish exposed to the API, EE2 (paper II) 
Two potentially robust and sensitive biomarkers of exposure were identified by 
exploring the hepatic global gene expression pattern in fish that were exposed to 
estrogens. The results from our own microarray analysis, which used both a high 
and a very low concentration of EE2, were combined with results from a meta-
analysis of microarray data from three additional studies. Two identified, 
sensitive biomarkers, nme2 and zp3, may increase the possibility to detect an 
exposure to low levels of estrogenic compounds in fish. In paper III, however, 
we showed that the regulation of nme2 is not specific or robust enough to use as 
a biomarker in a complex exposure situation. 
-  Microarray analysis of fish exposed to effluent from manufacturers of 
APIs (paper IV) 
Fish exposed to the effluent from PETL, which was diluted 1:500, had an altered 
expression of hepatic genes involved in the biotransformation and detoxification 
of chemicals and pharmaceuticals, increased Cyp1a enzyme activity and 
increased plasma phosphate levels. The pattern of differentially expressed genes 
did not clearly point to any specific group of substances, but the observed gene 
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regulations could serve as the basis from which to hypothesize mechanisms of 
sub-lethal toxicity and possible causative agents. The presented data support 
previously published data that showed that the wastewater treatment at PETL is 
insufficient and that there is an urgent need for improvement. 
- The expression of estrogen responsive genes in fish exposed to municipal 
effluents, processed with different treatment technologies (paper III) 
The advanced treatment technology ozonation was required during the STP 
process to remove all measured biological effects. However, advanced treatment 
technologies, such as ozonation, are generally expensive to implement. The 
addition of a sand-filtering step reduced the estrogen-induced response in male 
fish dramatically. In conclusion, this study provides valuable input into the 
assessment of advanced treatment technologies for the removal of estrogenic 
substances, given that the same influent was treated in parallel with a broad set 
of technologies and that the chemical analyses were combined with an in vivo 
assessment of estrogenic responses. 
This thesis contains examples of how genomic techniques can be helpful in the 
environmental risk assessment of pharmaceuticals. In this context comparative 
genomics could aid in the prioritization of drugs, species and endpoints, and 
techniques, such as microarray analysis, could be useful to increase the knowledge 
regarding the toxicological mode of action and to develop biomarkers of exposure. 
These biomarkers could then be used to evaluate the ability of different STP 
technologies to decrease the effects of residual pharmaceuticals in the environment.  
More knowledge is clearly needed to understand the risks that low 
concentrations of residual drugs pose to the aquatic environment. The risks that are 
connected to the release of very high concentrations of APIs at certain point sources 
are also important to assess and this might be the most urgent matter to resolve. 
High concentrations of APIs pose a significant threat to the local environment 
surrounding certain production sites and, in addition, high environmental 
concentrations of antibiotics could potentially be a more global threat.  
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